Last reviewed · How we verify
Loteprednol (Lotemax)
Loteprednol is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
Loteprednol is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, Post-operative inflammation following ocular surgery, Seasonal allergic conjunctivitis.
At a glance
| Generic name | Loteprednol (Lotemax) |
|---|---|
| Sponsor | Dr Salouti Eye Research Center |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Loteprednol is a soft corticosteroid designed to reduce inflammation and immune-mediated responses while minimizing systemic absorption and associated side effects. It binds to glucocorticoid receptors in ocular tissues, inhibiting the production of inflammatory mediators and reducing edema, erythema, and immune cell infiltration. The ester structure allows rapid metabolism, reducing the risk of elevated intraocular pressure compared to traditional corticosteroids.
Approved indications
- Inflammation and pain following ocular surgery
- Seasonal allergic conjunctivitis
- Uveitis
- Dry eye disease
Common side effects
- Elevated intraocular pressure
- Ocular irritation
- Conjunctival hyperemia
- Headache
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain (NA)
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period (PHASE4)
- Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus (EARLY_PHASE1)
- Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection (PHASE4)
- The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED (PHASE4)
- Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax (PHASE4)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loteprednol (Lotemax) CI brief — competitive landscape report
- Loteprednol (Lotemax) updates RSS · CI watch RSS
- Dr Salouti Eye Research Center portfolio CI